期刊文献+

PET/CT在诊断结直肠癌复发和转移中的应用 被引量:1

Application of PET/CT in Diagnosis of Recurrence and Metastasis of Colorectal Cancer
原文传递
导出
摘要 结直肠癌是最常见肿瘤之一,也是世界范围内主要的健康问题之一。随着诊疗水平的提高,结直肠癌患者的生存率也逐渐得到了改善。外科手术治疗是目前根治结直肠癌的唯一手段,但肿瘤的复发和转移仍是致死的重要原因之一,影响了生存率的进一步提高。早期诊断结直肠癌的复发有助于选择更为恰当的方案实施术后放疗或化疗,而对患者进行肿瘤转移的筛查则有助于更加准确地把握手术指征。
出处 《中国普外基础与临床杂志》 CAS 2012年第7期790-792,共3页 Chinese Journal of Bases and Clinics In General Surgery
  • 相关文献

参考文献41

  • 1陈万青,张思维,郑荣寿,雷正龙,李光琳,邹小农,赵平.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169. 被引量:329
  • 2Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in on-cology [J]. SeminNucl Med, 2000, 30(3): 150-185.
  • 3Strauss LG, Conti PS. The application of PET in clinical oncol- ogy [J]. J NuclMed, 1991, 32(4): 623-648; 649-650.
  • 4Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology [J]. Lancet Oncol, 2001,2(3): 157-164.
  • 5Hustinx R, B6nard F, Alavi A. Who body FDG-PET imaging in the management of patient with cancer [J]. Semin Nucl Med, 2002, 32(1): 35-46.
  • 6Smith TA. FDG uptake, tumor characteristics and response to therapy: areview [J]. Nucl MedCommun, 1998, 19(2): 97-105.
  • 7Ruers TJ, LangenhoffBS, Neeleman N, et al. Value of positron emission tomography with [ F- 18 ] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study [J]. J Clin Oneol, 2002, 20(2): 388-395.
  • 8Wahl ILL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT [ J ]. J Nucl Med, 2004, 45 Suppl 1 : 82S-95S.
  • 9Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology [J]. J Nucl Med, 2000, 41(8): 1369-1379.
  • 10Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET [J]. J Clin Oncol, 2004, 22(21): 4357-4368.

二级参考文献47

  • 1王爱娥,董书魁,王清娟,李雪丽.癌胚抗原在结直肠癌早期诊断和预后评估中的意义及其最新研究进展[J].中国临床康复,2004,8(32):7265-7267. 被引量:4
  • 2Bray F, Parkin DM, Evaluation of data quality in the cancer registry: Principles and methods. Part I : Comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45(5): 747-755.
  • 3Curado MP, Edwards B, Shin HR et al. Cancer incidence in five conti- nents, Vol. IX. IARC scientific publications No. 160[M]. Lyon: IARC, 2007.
  • 4Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IAtlC technical report No.19[M]. Lyon: IARC. 1994.
  • 5Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 6Felay J. The IARCcrgTools program [CP/OL]. http://www.iaer.com.fr/iarc- crgtools.htm, 2006.
  • 7Cromheecke M, Jong KP, Hoekstra HJ.Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol,1999, 25:451-463.
  • 8Tellez C, Benson AB, Lyster MT, et al.Phase Ⅱ trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature.Cancer, 1998, 82: 1250-1259.
  • 9Adam R. Current surgical strategies for the treatment of colorectal cancer liver metastases. Eur J Cancer, 2004, 2 Suppl:21-26.
  • 10Valls C, Andia E, Sanchez A, et al.Hepatic metastases from colorectal cancer:preoperative detection and assessment of resectability with helical CT. Radiology,2001, 218: 55-60.

共引文献387

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部